Cover Image

A multicenter phase 4 geriatric assessment directed trial to evaluate gemcitabine +/− nab-paclitaxel in elderly pancreatic cancer patients (GrantPax)

Show other versions (1)

In the group of elderly patients (≥70 years) with metastatic pancreatic ductal adenocarcinoma (mPDAC), it is not known who benefits from intensive 1st line nab-paclitaxel/gemcitabine (nab-p/gem) combination chemotherapy or who would rather suffer from increased toxicity. We aim to determine whether...

Full description

Saved in:
Bibliographic Details
Main Authors: Betge, Johannes (Author) , Chi-Kern, Jing (Author) , Schulte, Nadine (Author) , Belle, Sebastian (Author) , Gutting, Tobias (Author) , Burgermeister, Elke (Author) , Jesenofsky, Ralf (Author) , Ebert, Matthias (Author) , Härtel, Nicolai (Author)
Format: Article (Journal)
Language:English
Published: 18 July 2018
In: BMC cancer
Year: 2018, Volume: 18
ISSN:1471-2407
DOI:10.1186/s12885-018-4665-2
Online Access:Verlag, kostenfrei, Volltext: http://dx.doi.org/10.1186/s12885-018-4665-2
Verlag, kostenfrei, Volltext: https://doi.org/10.1186/s12885-018-4665-2
Get full text
Author Notes:Johannes Betge, Jing Chi-Kern, Nadine Schulte, Sebastian Belle, Tobias Gutting, Elke Burgermeister, Ralf Jesenofsky, Martin Maenz, Ulrich Wedding, Matthias P. Ebert and Nicolai Haertel
Description
Summary:In the group of elderly patients (≥70 years) with metastatic pancreatic ductal adenocarcinoma (mPDAC), it is not known who benefits from intensive 1st line nab-paclitaxel/gemcitabine (nab-p/gem) combination chemotherapy or who would rather suffer from increased toxicity. We aim to determine whether treatment individualization by comprehensive geriatric assessments (CGAs) improves functional outcome of the patients.
Item Description:Gesehen am 04.09.2018
Physical Description:Online Resource
ISSN:1471-2407
DOI:10.1186/s12885-018-4665-2

Similar Items